Postinduction Carbamazepine Clearance in an Adult Psychiatric Population

The objective of this study was to describe the postinduction clearance of carbamazepine (CBZ) in adult psychiatric patients by population pharmacokinetic analysis using the NONMEM program. Specifically, an estimate of CBZ clearance and insight into the effect of common patient characteristics on clearance were sought. Steady‐state trough CBZ serum concentrations, CBZ dosing history, concomitant drug administration, and other data from 45 patients were collected retrospectively. A one‐compartment model with first‐order absorption and first‐order elimination was used, with absorption rate, bioavailability, and volume of distribution fixed to literature values. No evidence was found that race, sex, age, ethanol use, smoking, and concomitant lithium significantly affected CBZ clearance. In the final model, clearance was based on lean body weight. The coefficient of variation for clearance estimates was 16.5%. Residual variability was modest. Estimates for volume of distribution, rates of absorption and elimination, and bioavailability could not be pursued rigorously. Although these results may assist in understanding CBZ disposition in this population, their general clinical application should be approached with caution.

[1]  A. Frigerio,et al.  Carbamazepine: biotransformation. , 1975, Advances in neurology.

[2]  R. Post,et al.  Profile of clinical efficacy and side effect of carbamazepine in psychiatric illness: relationship to blood and CSF levels of carbamazepine and its -10,11-epoxide metabolite. , 1984, Acta psychiatrica Scandinavica. Supplementum.

[3]  R. Post,et al.  Antidepressant effects of carbamazepine. , 1986, The American journal of psychiatry.

[4]  A. Kazdin,et al.  Carbamazepine and Behavior Therapy for Aggressive Behavior , 1983, Behavior modification.

[5]  J. Hull,et al.  The Effect of Disease States on Drug Pharmacokinetics , 1977 .

[6]  J. Boelaert,et al.  Should clearance be normalised to body surface or to lean body mass? , 1981, British journal of clinical pharmacology.

[7]  R. Post,et al.  Carbamazepine in manic-depressive illness: a new treatment. , 1980, The American journal of psychiatry.

[8]  R. Post,et al.  Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. , 1983, Archives of general psychiatry.

[9]  R. Summers,et al.  Carbamazepine Clearance in Paediatric Epilepsy Patients , 1989, Clinical pharmacokinetics.

[10]  W. Petrie,et al.  Carbamazepine treatment of selected affectively disordered inpatients. , 1982, The American journal of psychiatry.

[11]  Tw. Rall,et al.  Drugs effective in the therapy of the epilepsies , 1985 .

[12]  A. Kumps Dose-dependency of the ratio between carbamazepine serum level and dosage in patients with epilepsy. , 1981, Therapeutic drug monitoring.